Scholarlink

Abstract <p>In recent years, understanding of the key role of epithelial cytokines (IL-25, IL-33, and TSLP) in the development of respiratory tract inflammatory diseases has significantly expanded. These molecules, released by airway epithelium in response to allergens, pathogens, and damaging agents, act as alarmins, initiating a cascade of the Th2-mediated inflammation that leads to the IgE-mediated reactions, eosinophilic infiltration, and tissue remodeling. Beyond classical allergic processes, epithelial cytokines play a crucial role in the virus-induced exacerbations of respiratory diseases and pathogenesis of chronic obstructive pulmonary disease (COPD). Monoclonal antibody therapeutics targeting these cytokines have demonstrated efficacy in treating severe asthma. This review summarizes current data on contribution of TSLP, IL-33, and IL-25 to the respiratory tract inflammation and discusses the prospects of their targeted inhibition to improve therapeutic efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Role of Cytokines IL-25, IL-33, and TSLP in the Respiratory Tract Inflammation: Therapeutic Perspectives

  • 期刊论文

  • 发表日期：

    2026年1月1日

查看全文
  • Ekaterina D. Timotievich,
  • Igor P. Shilovskiy,
  • Danila A. Gurskii,
  • Anatoli D. Taganovich,
  • Aleksei G. Kadushkin,
  • Musa R. Khaitov

摘要

Abstract

In recent years, understanding of the key role of epithelial cytokines (IL-25, IL-33, and TSLP) in the development of respiratory tract inflammatory diseases has significantly expanded. These molecules, released by airway epithelium in response to allergens, pathogens, and damaging agents, act as alarmins, initiating a cascade of the Th2-mediated inflammation that leads to the IgE-mediated reactions, eosinophilic infiltration, and tissue remodeling. Beyond classical allergic processes, epithelial cytokines play a crucial role in the virus-induced exacerbations of respiratory diseases and pathogenesis of chronic obstructive pulmonary disease (COPD). Monoclonal antibody therapeutics targeting these cytokines have demonstrated efficacy in treating severe asthma. This review summarizes current data on contribution of TSLP, IL-33, and IL-25 to the respiratory tract inflammation and discusses the prospects of their targeted inhibition to improve therapeutic efficacy.